Trends in Pharmacological Sciences

Article	Citations
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential	357
Network pharmacology: curing causal mechanisms instead of treating symptoms	277
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic	274
Organ-on-a-Chip: A New Paradigm for Drug Development	228
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19	211
NLRP3 and pyroptosis blockers for treating inflammatory diseases	185
Causes and Consequences of Snake Venom Variation	176
Can Activation of NRF2 Be a Strategy against COVID-19?	154
In Vitro and Animal Models for SARS-CoV-2 research	149
A Perspective on Multi-target Drugs for Alzheimer’s Disease	145
Paving the Road for RNA Therapeutics	141
Tryptophan Metabolism as a Pharmacological Target	129
Emerging New Concepts of Degrader Technologies	113
Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs	102
Metformin and Systemic Metabolism	102
Drug Repurposing for Rare Diseases	101
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	99
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	92
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	92
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	89
Iron metabolism: pathophysiology and pharmacology	83
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	81
Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration	80
Physiological and pharmacological modulation of BAX	76
Targeting the Immune System for Ischemic Stroke	71

Progranulin as a therapeutic target in neurodegenerative diseases	70
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	70
Update and latest advances in antiretroviral therapy	70
AKAP Signaling Islands: Venues for Precision Pharmacology	69
Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis	67
Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades	65
Nrf2 for cardiac protection: pharmacological options against oxidative stress	64
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	60
Disrupting 3D printing of medicines with machine learning	59
Tackling TAMs for Cancer Immunotherapy: It’s Nano Time	59
Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance	59
Recent breakthroughs and future directions in drugging aquaporins	58
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality	55
Inhaled RNA Therapy: From Promise to Reality	55
Deciphering the TCR Repertoire to Solve the COVID-19 Mystery	54
Charting the Fragmented Landscape of Drug Synergy	53
Advances and challenges in therapeutic targeting of NRF2	49
Allosteric Modulation of Neurotransmitter Transporters as a Therapeutic Strategy	48
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	47
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	46
Polyunsaturated Fatty Acid Deuteration against Neurodegeneration	46
Carbon Monoxide: from Poison to Clinical Trials	43
Circulating tumor cells in precision medicine: challenges and opportunities	42
Structural and Functional Insights into Cannabinoid Receptors	39
Affinity Hydrogels for Protein Delivery	39
Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies	39
The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers	38
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	37
ER stress in obesity pathogenesis and management	37
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets	37
Biomolecular Corona Affects Controlled Release of Drug Payloads from Nanocarriers	37
Epigenetic Therapies for Osteoarthritis	36
Autoantibodies as Endogenous Modulators of GPCR Signaling	35
Nanocarriers for oral delivery of biologics: small carriers for big payloads	35
Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine	35
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy	35
Therapeutic RNA Strategies for Chronic Obstructive Pulmonary Disease	35
Accessing Intracellular Targets through Nanocarrier-Mediated Cytosolic Protein Delivery	35
Identifying Missing Biosynthesis Enzymes of Plant Natural Products	35
Structural perspective of class B1 GPCR signaling	35
Targeting Two-Pore Channels: Current Progress and Future Challenges	34
Present and future of microglial pharmacology	34
Biological Cells as Therapeutic Delivery Vehicles	34
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	34
High-power screening (HPS) empowered by DNA-encoded libraries	34
Context-Dependent Pharmacological Effects of Metformin on the Immune System	33
Drug–Exposome Interactions: The Next Frontier in Precision Medicine	33
Decoding pseudouridine: an emerging target for therapeutic development	33
Small Molecule Drug Discovery for Neglected Tropical Snakebite	33
Cancer Nanomedicines in an Evolving Oncology Landscape	32

Modulation of Ion Channels and Receptors by p11 (S100A10)	32
Compstatins: the dawn of clinical C3-targeted complement inhibition	31
Cholesterol – the devil you know; ceramide – the devil you don’t	31
CRISPR-based therapeutics: current challenges and future applications	30
Dawn of a New RAMPage	30
Can Growth Factors Cure Parkinson’s Disease?	29
3D cell cultures toward quantitative high-throughput drug screening	29
Acid-sensing ion channels as potential therapeutic targets	29
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age	29
Mouse models of atherosclerosis in translational research	28
Targeting natural killer cells to enhance vaccine responses	28
14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases	28
Membrane protein production and formulation for drug discovery	28
FOXO transcription factors as therapeutic targets in human diseases	27
Single-Cell Techniques and Deep Learning in Predicting Drug Response	27
The potential of long noncoding RNA therapies	27
Pharmacological tools to target NKCC1 in brain disorders	27
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the ‘Undruggable’ MYC in Pancreatic Cancer	27
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	26
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy	26
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics	26
Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment	25
Structural Biology of HIV Integrase Strand Transfer Inhibitors	25
Hypothalamic AMPK as a possible target for energy balance-related diseases	25
Developing Insulin Delivery Devices with Glucose Responsiveness	24
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	24
Nanodelivery of cGAS-STING activators for tumor immunotherapy	24
Fragment-based drug design facilitates selective kinase inhibitor discovery	23
Metastatic colorectal cancer: mechanisms and emerging therapeutics	23
Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs	23
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	23
Computational and artificial intelligence-based methods for antibody development	23
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells	23
Engineering ACE2 decoy receptors to combat viral escapability	22
Targeting of Potassium Channels in Cardiac Arrhythmias	22
Clinical Implications of Folate Transport in the Central Nervous System	22
AI-powered therapeutic target discovery	22
Targeting intracellular protein–protein interactions with macrocyclic peptides	22
Anticancer opportunities at every stage of chemokine function	22
Nanomedicine: controlling nanoparticle clearance for translational success	21
Histone post-translational modifications as potential therapeutic targets for pain management	21
Targeting SARS-CoV-2 papain-like protease in the postvaccine era	21
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent	21
Modulating the Blood–Testis Barrier Towards Increasing Drug Delivery	21
Mitochondrial dynamics proteins as emerging drug targets	21
The Convergence of Extracellular Vesicle and GPCR Biology	21
Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives	21
Structure-Based Virtual Screening Accelerates GPCR Drug Discovery	21
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	21
Ferrous Iron-Dependent Pharmacology	20
Microfluidic technologies for drug discovery and development: friend or foe?	20
Advances in Targeting GIRK Channels in Disease	20
Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future	20
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	19
Engineered antibody fusion proteins for targeted disease therapy	19
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	19
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic	19
Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells	18
Deep mutational scanning for therapeutic antibody engineering	18
Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions	18
BH3 Mimetics in AML Therapy: Death and Beyond?	18
Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors	17
Electroceuticals in the Gastrointestinal Tract	17
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	17
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics	17
Emerging strategies for beta cell transplantation to treat diabetes	17
Delivering AAV to the Central Nervous and Sensory Systems	17
Emerging Therapeutic Applications for Fumarates	16
A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2	16
Targeting KNa1.1 channels in KCNT1-associated epilepsy	16
Pharmacogenomics in treatment of depression and psychosis: an update	16
Unifying mechanism behind the onset of acquired epilepsy	16
Adenosine and inflammation: it's time to (re)solve the problem	16
The Potential of 19F NMR Application in GPCR Biased Drug Discovery	16
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype	15
Supramolecular nanomedicines through rational design of self-assembling prodrugs	15
Countermeasures in organophosphorus intoxication: pitfalls and prospects	15
Similarities between the Yin/Yang Doctrine and Hormesis in Toxicology and Pharmacology	15
Fluorescein Isothiocyanate Chitosan Nanoparticles in Oral Drug Delivery Studies	15
Beyond Deterministic Models in Drug Discovery and Development	15

Targeting sialylation to treat central nervous system diseases	14
Modulation of T cells by tryptophan metabolites in the kynurenine pathway	14
Multiparametric Assays for Accelerating Early Drug Discovery	14
Subtyping for pancreatic cancer precision therapy	14
Challenges and opportunities associated with rare-variant pharmacogenomics	14
Safety of medicines and vaccines – building next generation capability	14
Biomaterials, biological molecules, and polymers in developing vaccines	14
Interesting antifungal drug targets in the central metabolism of Candida albicans	13
Electrophilic Natural Products as Drug Discovery Tools	13
Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders	13
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	13
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules	13
Structural insights into ligand recognition and activation of angiotensin receptors	12
Targeting complement in neurodegeneration: challenges, risks, and strategies	12
Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds	12
Reactive chemistry for covalent probe and therapeutic development	12
The current toolbox for APOBEC drug discovery	12
Key metrics to expanding the pipeline of successful antibody–drug conjugates	12
Retinol Saturase: More than the Name Suggests	12
Therapeutic Targeting of IL-11 for Chronic Lung Disease	12
Reprogramming RNA processing: an emerging therapeutic landscape	12
Channeling Force in the Brain: Mechanosensitive Ion Channels Choreograph Mechanics and Malignancies	12
Identifying New Antimigraine Targets: Lessons from Molecular Biology	12
Targeting galectin-3 in inflammatory and fibrotic diseases	11
Recent advances in targeting autophagy in cancer	11
Monkeypox: potential vaccine development strategies	11
siRNA drug Leqvio (inclisiran) to lower cholesterol	11
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	11
Human Brain Neuropharmacology: A Platform for Translational Neuroscience	11
Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer	10
Gut microbiome-oriented therapy for metabolic diseases: challenges and opportunities towards clinical translation	10
GABAA receptors as targets for treating affective and cognitive symptoms of depression	10
Obesity pharmacotherapy: incretin action in the central nervous system	10
Omaveloxolone (SkyclarysTM) for patients with Friedreich’s ataxia	10
Tetrahydroprotoberberines: A Novel Source of Pharmacotherapies for Substance Use Disorders?	10
The structure and function of YTHDF epitranscriptomic m6A readers	10
Atypical chemokine receptors: emerging therapeutic targets in cancer	10
Peptides as a therapeutic strategy against Klebsiella pneumoniae	10
Targeting Solute Carrier Transporters through Functional Mapping	10
‘Channeling’ therapeutic discovery for epileptic encephalopathy through iPSC technologies	10
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	10
Casimersen for the treatment of Duchenne muscular dystrophy	10
Can CYP Inhibition Overcome Chemotherapy Resistance?	10
PUS7: a targetable epitranscriptomic regulator of glioblastoma growth	9
Determinants of Use of Biotherapeutics in sub-Saharan Africa	9
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	9
The pharmacology of the TMEM16A channel: therapeutic opportunities	9
Odorant receptors as potential drug targets	9
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	9
Epimimetics: Novel Therapeutics Targeting Epigenetic Mediators and Modulators	9
Targeted protein degrader development for cancer: advances, challenges, and opportunities	9
Efflux Limits Tumor Drug Delivery Despite Disrupted BBB	9
GPR35: from enigma to therapeutic target	9
Circadian clock-based therapeutics in chronic pulmonary diseases	8
Recent advances in the development of therapeutic peptides	8
Therapeutic inhibition of ferroptosis in neurodegenerative disease	8
Harnessing the Therapeutic Potential of ‘Rogue’ Antibodies	8
Wandering beyond small molecules: peptides as allosteric protein modulators	8
Chemogenetic Approaches to Explore the Functions of Free Fatty Acid Receptor 2	8
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	8
Thapsigargin: key to new host-directed coronavirus antivirals?	8
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models	8
Current landscape of preclinical models of diabetic cardiomyopathy	7
Artificial intelligence-driven drug development against autoimmune diseases	7
Advancing non-destructive analysis of 3D printed medicines	7
Electronic Health Records to Predict Gestational Diabetes Risk	7
Nanotherapeutic-directed approaches to analgesia	7
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies	7
Targeting stressor-induced dysfunctions in protein–protein interaction networks via epichaperomes	7
The Prognosis of Arthrofibroses: Prevalence, Clinical Shortcomings, and Future Prospects	7
Current clinical translation of microbiome medicines	7
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	7
Ganaxolone for management of seizures associated with CDKL5 deficiency disorder	7
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	7
Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain	7
Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses	7
Serial Crystallography for Structure-Based Drug Discovery	7
Targeting in silico GPCR conformations with ultra-large library screening for hit discovery	6
The consequences of particle uptake on immune cells	6
Leveraging aptamers for targeted protein degradation	6
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	6
A Novel Small Molecule Targets NKCC1 To Restore Synaptic Inhibition	6
Futibatinib (Lytgobi) for cholangiocarcinoma	6
Fluxes for Unraveling Complex Binding Mechanisms	6
Could dexmedetomidine be repurposed as a glymphatic enhancer?	6
Lipoxygenases in chronic liver diseases: current insights and future perspectives	6
Functional intersections between extracellular vesicles and oncolytic therapies	6
TRPC channels as emerging targets for seizure disorders	6
Beyond the NFAT Horizon: From Cyclosporine A-Induced Adverse Skin Effects to Novel Therapeutics	6
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	5
Small Molecules Restore Telomeres in Patient Stem Cells	5
A smart hospital-driven approach to precision pharmacovigilance	5
Proteomic approaches advancing targeted protein degradation	5
Biologics and cardiac disease: challenges and opportunities	5
Harnessing associative learning paradigms to optimize drug treatment	5